Klinisch orientierter Schwerpunkt
FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz
Rosner, Ann K.; Closs, Ellen I.; Habermeier, Alice et al.
Asymmetric dimethylarginine (ADMA) in retinal vein occlusion-Results from the Gutenberg RVO studyOPHTHALMOLOGE. 2020
Galle, Peter R.; Cheng, Ann-Lll; Qin, Shukui et al.
Atezolizumab (ATEZO) plus Bevacizumab ( BEV) vs Sorafenib (SOR) in Patients (PTS) with Unresectable Hepatocellular Carcinoma (HCC): Phase 3 Results from Imbrave150ONCOLOGY RESEARCH AND TREATMENT. Bd. 43. 2020 S. 220-220
Finn, Richard S.; Qin, Shukui; Ikeda, Masafumi et al.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNEW ENGLAND JOURNAL OF MEDICINE. Bd. 382. H. 20. 2020 S. 1894-1905
Matos-Rodrigues, Gabriel E.; Grigaravicius, Paulius; Lopez, Bernard S. et al.
ATRIP protects progenitor cells against DNA damage in vivoCELL DEATH & DISEASE. Bd. 11. H. 10. 2020
Matos-Rodrigues, Gabriel E.; Grigaravicius, Paulius; Lopez, Bernard S. et al.
ATRIP protects progenitor cells against DNA damage in vivo (vol 11, 923, 2020)CELL DEATH & DISEASE. Bd. 11. H. 12. 2020
Allmann, Sebastian; Mayer, Laura; Olma, Jessika et al.
Benzo[a]pyrene represses DNA repair through altered E2F1/E2F4 function marking an early event in DNA damage-induced cellular senescenceNUCLEIC ACIDS RESEARCH. Bd. 48. H. 21. 2020 S. 12085-12101
Kaiser, Jan Christian; Blettner, Maria; Stathopoulos, Georgios T.
Biologically based models of cancer risk in radiation researchINTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2020
Eichkorn, D.; Vosshagen, F.; Zeilinger, R. et al.
Biomarker-based early detection of epithelial ovarian cancer based on a 5-protein signature in patients serumGEBURTSHILFE UND FRAUENHEILKUNDE. Bd. 80. H. 10. 2020 S. E188-E188
Böckers, Madeleine; Paul, Norbert; Efferth, T
Bisphenolic compounds alter gene expression in MCF-7 cells through interaction with estrogen receptor αToxicology and Applied Pharmacology. Bd. 399. 2020 S. 115030
Mai, Elias K.; Miah, Kaya; Bertsch, Uta et al.
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageLEUKEMIA. 2020